Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Craig P. Carden, Debashis Sarker, Sophie Postel-Vinay, Timothy A. Yap, Gerthardt Attard, Udai Banerji, Michelle D. Garrett, George V. Thomas, Paul Workman, Stan B. Kaye, Johann S. de Bono

Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

58 Citations (Scopus)

Résumé

Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to molecular-targeted agents, have the potential to enrich these trials with patients more likely to benefit. Doing so could maximize the efficiency of anticancer drug development by facilitating earlier clinical qualification of predictive biomarkers and generating valuable information on cancer biology. In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents.

langue originaleAnglais
Pages (de - à)88-97
Nombre de pages10
journalDrug Discovery Today
Volume15
Numéro de publication3-4
Les DOIs
étatPublié - 1 févr. 2010
Modification externeOui

Contient cette citation